본문 바로가기
bar_progress

Text Size

Close

Cymax to Develop 'Lower Limb Rehabilitation Assistive Robot' with Seoul Asan Medical Center

[Asia Economy Reporter Hyunseok Yoo] Cymax is developing a lower limb rehabilitation assist robot in collaboration with Seoul Asan Medical Center. The company plans to leverage its various robotic technologies to respond to new business opportunities starting with this project.


According to industry sources on the 13th, Cymax announced on its website the day before that it signed a Memorandum of Understanding (MOU) for mutual cooperation with the Medical Device Clinical Trial Support Center of Seoul Asan Medical Center to jointly develop a 'lower limb rehabilitation assist robot.'


Both organizations agreed to utilize their respective know-how and resources to accelerate the development and clinical application of the lower limb rehabilitation assist robot and to mutually cooperate in the future commercialization of the robot.


The 'lower limb rehabilitation assist robot' is an intelligent robotic rehabilitation training system designed to restore and strengthen lower limb muscle strength for the elderly and disabled. Cymax explained on its website, "In preparation for the rapidly progressing aging population and the era of intelligent robotics industry, Cymax merged with CyborgLab, a specialized robotics company, in February to strengthen the technological competitiveness of its existing semiconductor wafer transfer robots," adding, "Based on the diverse robotic technologies possessed by CyborgLab, including medical assist robots and collaborative robots, we are swiftly responding to new business opportunities."


Meanwhile, on the 8th, Cymax disclosed that its consolidated operating profit for the first quarter was preliminarily estimated at 8.039 billion KRW, a 2376% increase compared to the same period last year. During the same period, sales rose 200% to 51.827 billion KRW, and net profit increased by 366.8% to 3.554 billion KRW.


© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Special Coverage


Join us on social!

Top